MOUNTAIN VIEW, Calif., May 16, 2012 /PRNewswire/ -- Tissue engineering has the ability to hasten the treatment of wounds and other conditions. This procedure's rising popularity as an alternative to tissue or organ transplantation has sparked off a spate of technology and product advancements in various segments of the market.
New analysis from Frost & Sullivan's (http://www.medicaldevices.frost.com) U.S. Tissue Engineering Markets research finds that tissue engineering has shown promise as an important solution to treat tissue and organ failure. It addresses these problems by implanting natural, synthetic or semisynthetic tissues that are fully functional from the start, or grow into the required functionality.
If you are interested in more information on this research, please send an email to Britni Myers, Corporate Communications, at [email protected], with your full name, company name, job title, telephone number, company email address, company web site, city, state and country.
One such advancement is the availability of biomaterials that act as scaffolds for tissue repair and reconstruction, or for the deposition of engineered tissues and cells before implantation. In the biological component of tissue engineering, scientists have made rapid strides in identifying new cell types for use in tissue regeneration. These two developments together open numerous growth opportunities in the market.
Meanwhile, biologic materials have been steadily making a mark as an accepted adjunct tissue repair.
"Biologics have garnered considerable interest since its introduction in the 1990s; however, companies have been unable to provide adequate data to demonstrate their superior efficacy over synthetics," said Frost & Sullivan Senior Industry Analyst Aarti Shetty. "As biologics are much more expensive than synthetics, reports of successful surgeries will encourage patients to choose premium products, thus raising the market's revenues."
Despite the extensive R&D efforts, the market has not witnessed a perfect product yet, giving ample scope for smaller companies to prove their mettle. The medical community has, for awhile, grappled with the issue of limited access to donors or donated tissue and organs on time. Moreover, tissue engineering is becoming increasingly complicated, as the market is exploring the application of these products in various body parts. The lack of fundamental understanding of tissue regeneration mechanisms further slows down product development.
"As more data is published by companies and academic institutions, the impact of tissue engineering products and mechanisms on different applications will become more apparent," said Shetty. "Enhanced understanding will make physicians comfortable with the products and their applications, aiding their higher adoption."
Some market segments, such as chronic wound care, have generated more revenues than others, as their higher number of clinical trials has improved the standard of care in treating wounds. Currently, researchers are engaged in ground-breaking and innovative work in this area.
"With greater technological breakthroughs, there will be a better understanding of the various processes that affect the development of tissue engineering products and the ways in which they react with the human body," said Shetty. "In the future, companies will launch many technologically superior tissue engineering products that offer enhanced ease-of-use, long-term effects, and patient comfort."
U.S. Tissue Engineering Markets is part of the Advanced Medical Technologies Growth Partnership Services program, which also includes research in the following markets: U.S. Hernia Repair Market: Overview and Opportunities Going Forward; Less Pain, More Gain–Analysis of the Advanced Wound Management Market in Western Europe; and Advanced Wound Care Management in Taiwan. All research services included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.
Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.
- The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
- The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.
For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?
U.S. Tissue Engineering Markets
Corporate Communications – North America
E: [email protected]
SOURCE Frost & Sullivan